39 / 60
39
Scientific programme
Saturday, 30 May 2015
P-26-004 Edinburgh pilot study of a psycho
education programme for adults with
Attention-Deficit/Hyperactivity Disorder
R. Jones, United Kingdom
P-26-005 Dialectical behaviorally inspired psycho-
therapy for adults ADHD: Preliminary
results
N. Perroud, Switzerland
P. Prada, J. Zimmermann, J.-M. Aubry,
R. Nicastro
P-26-006 CBT for adult ADHD and implementation
strategies: An open pilot study
R. Ramsay, USA
A. Rostain
P-26-007 CBT for adult ADHD: An open pilot study
of effects on functional status
R. Ramsay, USA
A. Rostain
P-26-008 The effects of a Self-Alert Training (SAT)
programme in adults with ADHD
S. Salomone, United Kingdom
G. R. Fleming, J. M. Shanahan, M. Castorina,
J. Bramham, R. G. O´Connell, I. H. Robertson
P-26-009 rTMS of 1Hz helps to reduce MPH in a
patient suffering from ADHD
H. Niederhofer, Germany
P-26-010 Cognitive behavioral therapy for adults
with Attention-Deficit/Hyperactivity
Disorder: Protocol of a randomized con-
trolled trial
F. Huang, People‘s Republic of China
Q.-J. Qian, Y.-F. Wang
P-26-011 NIRS neurofeedback as a treatment
method in adult Attention-Deficit/Hyper
activity Disorder
B. Barth, Germany
A.-C. Ehlis, K. Mayer, F. Häußinger, A. Fall
gatter, U. Strehl
P-27
Guided Poster Tour
16:00–17:30
Hall 2 – Poster Area
Pharmacological treatment – children and
adolescents III
Chair:
J. Halperin, USA
P-27-001 Predictors of relapse or maintenance of re-
sponse of Attention-Deficit/Hyperactivity
Disorder symptoms after discontinuation
of long-term treatment with atomoxetine
J. Thome, Germany
R. Escobar, S. Lipsius, H. Upadhyaya
P-27-002 Stroop interference in patients with
Attention-Deficit/Hyperactivity Disorder
M. Vallejo, Spain
P. deCastro-Manglano, A. Diez-Suárez, A.
Figueroa-Quintana, J. J. Marín-Méndez, C.
Soutullo-Esperón
P-27-003 The effect of GXR (guanfacine) as adjunc-
tive treatment with stimulant therapy on
executive function and quality of life:
A phase IV, single-centre, randomized,
double-blind, placebo controlled, crosso-
ver evaluation
J. van Stralen, Canada
E. Corsi
P-27-004 Clinical response and symptomatic remis-
sion in adolescents with Attention-Deficit/
Hyperactivity Disorder receiving guanfa-
cine extended release in a phase 3 study
T. E. Wilens, United Kingdom
L. Harper, J. L. Young, V. Sikirica, G. Rynkowski,
B. Dirks, A. Cutler
P-27-005 Safety outcomes from a phase 4, open-
label, multicentre, 2-year study of lis-
dexamfetamine dimesylate in children
and adolescents with Attention-Deficit/
Hyperactivity Disorder
A. Zuddas, Italy
T. Banaschewski, P. Nagy, C. Soutullo, B. Yan,
B. Caballero, D. R. Coghill
P-27-006 Mirtazapine for weight loss and insomnia
associated with methylphenidate: A chart
review
S. Herguner, Turkey
A. Herguner